Published in Obesity and Diabetes Week, May 17th, 2004
"Our research has determined that ATL compounds which block adenosine receptors lower blood glucose in rats and mice. The focus of the research funded by this grant will expand testing on a new family of compounds that are expected to be more efficacious than previous compounds," said Joel Linden, PhD, cofounder of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.